Anti-GITR agonistic antibody therapy has been shown to cause tumor regression in a number of preclinical non-CNS tumor models18,20 and is under evaluation as monotherapy (NCT01239134) and in combination with aPD1 therapy in a number of clinical trials (NCT04021043, NCT02740270, NCT02628574, NCT02598960, and NCT04225039). This evidence concerns the gene TNFRSF18 and neoplasm.